- Home
- DEVS vs ADXN Comparison
DEVS vs ADXN Comparison
Compare DEVS & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- ADXN
- Stock Information
- Founded
- DEVS N/A
- ADXN 2002
- Country
- DEVS Canada
- ADXN Switzerland
- Employees
- DEVS N/A
- ADXN N/A
- Industry
- DEVS
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- DEVS
- ADXN Health Care
- Exchange
- DEVS NYSE
- ADXN Nasdaq
- Market Cap
- DEVS 6.4M
- ADXN 7.5M
- IPO Year
- DEVS N/A
- ADXN N/A
- Fundamental
- Price
- DEVS $0.21
- ADXN $8.16
- Analyst Decision
- DEVS
- ADXN Strong Buy
- Analyst Count
- DEVS 0
- ADXN 1
- Target Price
- DEVS N/A
- ADXN $30.00
- AVG Volume (30 Days)
- DEVS 260.6K
- ADXN 8.4K
- Earning Date
- DEVS 05-12-2025
- ADXN 06-05-2025
- Dividend Yield
- DEVS N/A
- ADXN N/A
- EPS Growth
- DEVS N/A
- ADXN N/A
- EPS
- DEVS N/A
- ADXN 0.06
- Revenue
- DEVS N/A
- ADXN $701,260.00
- Revenue This Year
- DEVS N/A
- ADXN N/A
- Revenue Next Year
- DEVS N/A
- ADXN N/A
- P/E Ratio
- DEVS N/A
- ADXN $1.06
- Revenue Growth
- DEVS N/A
- ADXN N/A
- 52 Week Low
- DEVS $0.18
- ADXN $6.51
- 52 Week High
- DEVS $1.91
- ADXN $17.05
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- ADXN 58.71
- Support Level
- DEVS N/A
- ADXN $6.75
- Resistance Level
- DEVS N/A
- ADXN $8.20
- Average True Range (ATR)
- DEVS 0.00
- ADXN 0.42
- MACD
- DEVS 0.00
- ADXN 0.11
- Stochastic Oscillator
- DEVS 0.00
- ADXN 97.63
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.